Hearing loss, autosomal dominant 71

Summary

Hearing loss, autosomal dominant 71 (MONDO:0033258) is a disease with 1 cohort gene.

At a glance

• Cohort genes: 1
• ClinVar variants: 30

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hearing loss, autosomal dominant 71
Mondo ID	MONDO:0033258
OMIM	617605
DOID	DOID:0080267
UMLS	C4539881
MedGen	1621646
GARD	0018147
Is cancer (heuristic)	no

Also known as: autosomal dominant nonsyndromic deafness 71 · deafness, autosomal dominant 71 · DFNA71

Data availability: 30 ClinVar variants · 3 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal dominant disease › autosomal dominant nonsyndromic hearing loss › hearing loss, autosomal dominant 71

Related subtypes (75): autosomal dominant nonsyndromic hearing loss 1, autosomal dominant nonsyndromic hearing loss 2A, autosomal dominant nonsyndromic hearing loss 4A, autosomal dominant nonsyndromic hearing loss 6, autosomal dominant nonsyndromic hearing loss 5, autosomal dominant nonsyndromic hearing loss 10, autosomal dominant nonsyndromic hearing loss 11, autosomal dominant nonsyndromic hearing loss 9, autosomal dominant nonsyndromic hearing loss 7, autosomal dominant nonsyndromic hearing loss 12, autosomal dominant nonsyndromic hearing loss 3A, autosomal dominant nonsyndromic hearing loss 13, autosomal dominant nonsyndromic hearing loss 15, autosomal dominant nonsyndromic hearing loss 17, autosomal dominant nonsyndromic hearing loss 16, autosomal dominant nonsyndromic hearing loss 20, autosomal dominant nonsyndromic hearing loss 23, autosomal dominant nonsyndromic hearing loss 25, autosomal dominant nonsyndromic hearing loss 18, autosomal dominant nonsyndromic hearing loss 24, autosomal dominant nonsyndromic hearing loss 22, autosomal dominant nonsyndromic hearing loss 30, autosomal dominant nonsyndromic hearing loss 36, autosomal dominant nonsyndromic hearing loss 21, autosomal dominant nonsyndromic hearing loss 44, autosomal dominant nonsyndromic hearing loss 48, autosomal dominant nonsyndromic hearing loss 41, autosomal dominant nonsyndromic hearing loss 49, autosomal dominant nonsyndromic hearing loss 43, autosomal dominant nonsyndromic hearing loss 28, autosomal dominant nonsyndromic hearing loss 31, autosomal dominant nonsyndromic hearing loss 47, autosomal dominant auditory neuropathy 1, autosomal dominant nonsyndromic hearing loss 53, autosomal dominant nonsyndromic hearing loss 27, autosomal dominant nonsyndromic hearing loss 59, autosomal dominant nonsyndromic hearing loss 3B, autosomal dominant nonsyndromic hearing loss 2B, autosomal dominant nonsyndromic hearing loss 50, autosomal dominant nonsyndromic hearing loss 51, autosomal dominant nonsyndromic hearing loss 64, autosomal dominant nonsyndromic hearing loss 33, autosomal dominant nonsyndromic hearing loss 4B, autosomal dominant nonsyndromic hearing loss 56, autosomal dominant nonsyndromic hearing loss 54, autosomal dominant nonsyndromic hearing loss 58, autosomal dominant nonsyndromic hearing loss 65, autosomal dominant nonsyndromic hearing loss 67, autosomal dominant nonsyndromic hearing loss 40, autosomal dominant nonsyndromic hearing loss 69, autosomal dominant nonsyndromic hearing loss 68, autosomal dominant nonsyndromic hearing loss 70, autosomal dominant nonsyndromic hearing loss 66, hearing loss, autosomal dominant 74, hearing loss, autosomal dominant 77, hearing loss, autosomal dominant 81, hearing loss, autosomal dominant 82, hearing loss, autosomal dominant 83, hearing loss, autosomal dominant 84, hearing loss, autosomal dominant 80, hearing loss, autosomal dominant 37, hearing loss, autosomal dominant 75, hearing loss, autosomal dominant 76, hearing loss, autosomal dominant 72, hearing loss, autosomal dominant 73, hearing loss, autosomal dominant 34, with or without inflammation, hearing loss, autosomal dominant 78, hearing loss, autosomal dominant 79, hearing loss, autosomal dominant 85, hearing loss, autosomal dominant 86, hearing loss, autosomal dominant 87, hearing loss, autosomal dominant 88, hearing loss, autosomal dominant 89, hearing loss, autosomal dominant 90, autosomal dominant nonsyndromic hearing loss 91

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

30 retrieved; paginated sample, class counts are floors:

12 benign, 8 uncertain significance, 7 conflicting classifications of pathogenicity, 2 benign/likely benign, 1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
1065611	NM_001378457.1(DMXL2):c.918G>T (p.Gln306His)	DMXL2	Pathogenic	no assertion criteria provided
1397986	NM_001378457.1(DMXL2):c.3108G>T (p.Glu1036Asp)	DMXL2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1980737	NM_001378457.1(DMXL2):c.8219G>A (p.Arg2740His)	DMXL2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2062918	NM_001378457.1(DMXL2):c.6035A>C (p.Gln2012Pro)	DMXL2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2162657	NM_001378457.1(DMXL2):c.1463C>T (p.Thr488Met)	DMXL2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2192055	NM_001378457.1(DMXL2):c.5093A>G (p.Asn1698Ser)	DMXL2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
431430	NM_001378457.1(DMXL2):c.7250G>A (p.Arg2417His)	DMXL2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
953072	NM_001378457.1(DMXL2):c.6247G>A (p.Ala2083Thr)	DMXL2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1033358	NM_001378457.1(DMXL2):c.8527-15_8527-11dup	DMXL2	Uncertain significance	criteria provided, single submitter
1402171	NM_001378457.1(DMXL2):c.1339G>A (p.Asp447Asn)	DMXL2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1471673	NM_001378457.1(DMXL2):c.7543A>G (p.Met2515Val)	DMXL2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1954495	NM_001378457.1(DMXL2):c.8362G>A (p.Val2788Ile)	DMXL2	Uncertain significance	criteria provided, multiple submitters, no conflicts
2442168	NM_001378457.1(DMXL2):c.4475A>G (p.Lys1492Arg)	DMXL2	Uncertain significance	criteria provided, single submitter
2627787	NM_001378457.1(DMXL2):c.430G>A (p.Glu144Lys)	DMXL2	Uncertain significance	no assertion criteria provided
2628079	NM_001378457.1(DMXL2):c.2763A>T (p.Leu921Phe)	DMXL2	Uncertain significance	criteria provided, single submitter
3577360	NM_001378457.1(DMXL2):c.5393G>A (p.Arg1798His)	DMXL2	Uncertain significance	criteria provided, single submitter
1178042	NM_001378457.1(DMXL2):c.2823C>T (p.Asn941=)	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1227653	NM_001378457.1(DMXL2):c.27A>G (p.Gly9=)	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1233890	NM_001378457.1(DMXL2):c.1346-39A>G	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1234931	NM_001378457.1(DMXL2):c.6833+11del	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1239392	NM_001378457.1(DMXL2):c.-36A>C	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1242526	NM_001378457.1(DMXL2):c.8077-22C>T	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1248420	NM_001378457.1(DMXL2):c.1490C>T (p.Thr497Met)	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1255508	NM_001378457.1(DMXL2):c.7520+35del	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1255509	NM_001378457.1(DMXL2):c.5051+23G>A	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1255510	NM_001378457.1(DMXL2):c.4908A>G (p.Gly1636=)	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1255511	NM_001378457.1(DMXL2):c.3862T>C (p.Ser1288Pro)	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
1255512	NM_001378457.1(DMXL2):c.81C>T (p.Pro27=)	DMXL2	Benign	criteria provided, multiple submitters, no conflicts
715828	NM_001378457.1(DMXL2):c.7809-6del	DMXL2	Benign/Likely benign	criteria provided, multiple submitters, no conflicts
782886	NM_001378457.1(DMXL2):c.3860G>T (p.Ser1287Ile)	DMXL2	Benign/Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 13 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
DMXL2	Supportive	Autosomal dominant	autosomal dominant nonsyndromic hearing loss	13

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
DMXL2	Orphanet:1934	Early infantile developmental and epileptic encephalopathy
DMXL2	Orphanet:453533	Polyendocrine-polyneuropathy syndrome
DMXL2	Orphanet:90635	Rare autosomal dominant non-syndromic sensorineural deafness type DFNA

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
DMXL2	HGNC:2938	ENSG00000104093	Q8TDJ6	DmX-like protein 2	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
DMXL2	DmX-like protein 2	May serve as a scaffold protein for MADD and RAB3GA on synaptic vesicles.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	1	17.3×	0.058

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
DMXL2	Scaffold/PPI	no		WD40_rpt, WD40/YVTN_repeat-like_dom_sf, Rav1p_C

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
leukocyte	1
monocyte	1
mononuclear cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
DMXL2	269	ubiquitous	marker	monocyte, mononuclear cell, leukocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
DMXL2	1,090

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
DMXL2	Q8TDJ6

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
vacuolar acidification	1	732.7×	0.001	DMXL2

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
DMXL2	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	DMXL2

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
DMXL2	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.